Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer - Related Studies

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

This study has been completed.

Study NCT00075270. Last updated on November 26, 2008. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Metastatic Breast Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms

3	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

4	Interventions listed in this trial
		Paclitaxel
		GW572016 (Lapatinib)

5	Additional drug interventions recognized in this trial
		Lapatinib

6	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Enzyme Inhibitors
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		GlaxoSmithKline